- What this builds on, and the important void that it fills, in a way, is, you know, how-- It's one thing to be able to give it to people that are ineligible for TPA, and in fact there is a clinical trial underway doing just that, ESCAPE-NEXT. But, there's an even larger population of patients that are getting TPA, that we really think will benefit from this drug as well. Because even though TPA dissolves clot, and restores blood flow, the majority of patients that are treated with TPA still go on and have serious long-term consequences of stroke. So there's a lotta room for improvement, even in the patients that are TPA treated. So this new formulation, this new way of delivering this drug through these nano particles, that may get around this TPA effect, and may allow it to be effective, even in patients that get TPA.